This CPB has been revised to state that ketamine (intranasal, intravenous, oral, or subcutaneous) is considered experimental and investigational for the treatment of acute pain, central body pain, chronic pain, neuropathic pain, post-concussion syndrome, and sickle cell vaso-occlusive crises.

The title of this CPB has been changed to “Ketamine for the Treatment of Depression and Other Selected Indications”.